nach oben

Endocrine

Erschienen in:

01.02.2012 | Review

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

verfasst von: Absalon D. Gutierrez, Ashok Balasubramanyam

Erschienen in: Endocrine | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased prevalence of impaired glucose tolerance, diabetes mellitus, and cardiometabolic syndrome. While much attention has been focused on the lipid and cardiovascular disorders, few investigations have attempted to characterize the prevalence, incidence, etiology, mechanisms, and management of glycemic disorders in HIV patients. In this review, we have focused specifically on a comprehensive assessment of dysglycemia in the context of HIV infection and HAART.

I.J. Paik, D.P. Kotler, The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract. Res. Clin. Endocrinol. Metab. 25, 469–478 (2011)PubMedCrossRef

W.M. El-Sadr et al., Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 6, 114–121 (2005)PubMedCrossRef

F. Visnegarwala, L. Chen, S. Raghavan, E. Tedaldi, Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J. Infect. 50, 331–337 (2005)PubMedCrossRef

P.C. Tien et al., Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study. AIDS 21, 1739–1745 (2007)PubMedCrossRef

C. Hadigan et al., Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32, 130–139 (2001)PubMedCrossRef

T.T. Brown et al., Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179–1184 (2005)PubMedCrossRef

M. Beregszaszi et al., Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J. Acquir. Immune Defic. Syndr. 40, 161–168 (2005)PubMedCrossRef

R. Palacios et al., Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir. Ther. 11, 529–535 (2006)PubMed

S. De Wit et al., Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31, 1224–1229 (2008)PubMedCrossRef

10.

V. Estrada et al., Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 55, 940–945 (2006)PubMedCrossRef

11.

C. Jerico et al., Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28, 132–137 (2005)PubMedCrossRef

12.

M.E. Sobieszczyk et al., Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J. Acquir. Immune Defic. Syndr. 48, 272–280 (2008)PubMedCrossRef

13.

K. Samaras et al., Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30, 113–119 (2007)PubMedCrossRef

14.

K. Mondy et al., Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin. Infect. Dis. 44, 726–734 (2007)PubMedCrossRef

15.

C. Gazzaruso et al., Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J. Hypertens. 21, 1377–1382 (2003)PubMedCrossRef

16.

G. Meininger et al., Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51, 260–266 (2002)PubMedCrossRef

17.

C. Hadigan et al., Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J. Clin. Endocrinol. Metab. 84, 1932–1937 (1999)PubMedCrossRef

18.

A.A. Howard et al., Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. 7, 389–396 (2006)PubMedCrossRef

19.

S.H. Mehta, R.D. Moore, D.L. Thomas, R.E. Chaisson, M.S. Sulkowski, The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 33, 577–584 (2003)PubMedCrossRef

20.

M.J. Glesby et al., Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women’s Interagency HIV Study. Antivir. Ther. 15, 571–577 (2010)PubMedCrossRef

21.

F.A. Ramirez-Marrero et al., Prevalence of cardiometabolic risk factors in Hispanics living with HIV. Ethn. Dis. 20, 423–428 (2010)PubMed

22.

S.L. Samson et al., Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp. Clin. Trials 27, 518–530 (2006)PubMedCrossRef

23.

A. Balasubramanyam et al., Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J. Clin. Endocrinol. Metab. 96, 2236–2247 (2011)PubMedCrossRef

24.

M. Mary-Krause et al., Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17, 2479–2486 (2003)PubMedCrossRef

25.

N. Friis-Moller et al., Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993–2003 (2003)PubMedCrossRef

26.

V.A. Triant, H. Lee, C. Hadigan, S.K. Grinspoon, Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506–2512 (2007)PubMedCrossRef

27.

S.W. Worm et al., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201, 318–330 (2010)PubMedCrossRef

28.

F. Magkos, C.S. Mantzoros, Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism 60, 749–753 (2011)PubMedCrossRef

29.

E.Y. Chan et al., Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production. J. Virol. 81, 7571–7583 (2007)PubMedCrossRef

30.

S. Rasheed, J.S. Yan, A. Lau, A.S. Chan, HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study. PLoS One 3, e3003 (2008)PubMedCrossRef

31.

G. Aragones et al., Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. BMC Gastroenterol. 10, 92 (2010)PubMedCrossRef

32.

C. Grunfeld et al., Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90, 154–162 (1991)PubMed

33.

C. Grunfeld et al., Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045–1052 (1992)PubMedCrossRef

34.

S. Das et al., In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 49, 538–542 (2006)PubMedCrossRef

35.

R.V. Sekhar et al., Metabolic basis of HIV-lipodystrophy syndrome. Am. J. Physiol. Endocrinol. Metab. 283, E332–E337 (2002)PubMed

36.

P. Limone et al., Insulin resistance in HIV-infected patients: relationship with pro-inflammatory cytokines released by peripheral leukocytes. J. Infect. 47, 52–58 (2003)PubMedCrossRef

37.

S. Shrivastav et al., Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol. Endocrinol. 22, 234–247 (2008)PubMedCrossRef

38.

T. Kino, M. Mirani, S. Alesci, G.P. Chrousos, AIDS-related lipodystrophy/insulin resistance syndrome. Horm. Metab. Res. 35, 129–136 (2003)PubMedCrossRef

39.

P. Koutkia, K. Eaton, S.M. You, J. Breu, S. Grinspoon, Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. AIDS 20, 855–862 (2006)PubMedCrossRef

40.

C. Grady, M. Ropka, R. Anderson, H.C. Lane, Body composition in clinically stable men with HIV infection. J. Assoc. Nurses AIDS Care 7, 29–38 (1996)PubMedCrossRef

41.

V. Soriano et al., Antiretroviral drugs and liver injury. AIDS 22, 1–13 (2008)PubMedCrossRef

42.

D.A. Wohl et al., Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis. 43, 645–653 (2006)PubMedCrossRef

43.

J.S. Currier, D.V. Havlir, Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2004, San Francisco, California, USA. Top. HIV Med. 12, 31–45 (2004)PubMed

44.

R.V. Sekhar et al., Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am. J. Clin. Nutr. 81, 1405–1410 (2005)PubMed

45.

S.K. Gan et al., Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 51, 3163–3169 (2002)PubMedCrossRef

46.

G.M. Behrens et al., Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J. Clin. Invest. 110, 1319–1327 (2002)PubMed

47.

J. Sutinen et al., Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16, 2183–2193 (2002)PubMedCrossRef

48.

S.B. Haugaard et al., Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells. Am. J. Physiol. Endocrinol. Metab. 287, E677–E685 (2004)PubMedCrossRef

49.

T.T. Brown, K. Tassiopoulos, R.J. Bosch, C. Shikuma, G.A. McComsey, Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 33, 2244–2249 (2010)PubMedCrossRef

50.

G.F. de Larranaga, S.D. Wingeyer, L.M. Puga, B.S. Alonso, J.A. Benetucci, Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur. J. Clin. Microbiol. Infect. Dis. 25, 98–103 (2006)PubMedCrossRef

51.

M. Duong et al., Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 245–250 (2001)PubMedCrossRef

52.

A. Balasubramanyam, R.V. Sekhar, HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution. Res. Initiat. Treat. Action 12, 5–11 (2006)PubMed

53.

C. Hadigan, J. Liebau, M. Torriani, R. Andersen, S. Grinspoon, Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J. Clin. Endocrinol. Metab. 91, 4438–4444 (2006)PubMedCrossRef

54.

B.H. McGovern et al., Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin. Infect. Dis. 43, 365–372 (2006)PubMedCrossRef

55.

M.S. Sulkowski et al., Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19, 585–592 (2005)PubMedCrossRef

56.

N. Crum-Cianflone et al., Nonalcoholic fatty liver disease among HIV-infected persons. J. Acquir. Immune Defic. Syndr. 50, 464–473 (2009)PubMedCrossRef

57.

G.C. Farrell, C.Z. Larter, Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99–S112 (2006)PubMedCrossRef

58.

A.E. Ogedegbe, D.L. Thomas, A.M. Diehl, Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect. Dis. 3, 329–337 (2003)PubMedCrossRef

59.

N. Stefan, H.U. Haring, The metabolically benign and malignant fatty liver. Diabetes 60, 2011–2017 (2011)PubMedCrossRef

60.

J.M. Schwarz et al., Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87, 942 (2002)PubMedCrossRef

61.

S. D’Amico et al., Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am. J. Clin. Nutr. 84, 204–211 (2006)PubMed

62.

J.C. Lo et al., The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 86, 3480–3487 (2001)PubMedCrossRef

63.

D.P. Kotler et al., Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35, 239–252 (2004)PubMedCrossRef

64.

P. Koutkia, B. Canavan, J. Breu, S. Grinspoon, Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J. Clin. Endocrinol. Metab. 90, 2154–2160 (2005)PubMedCrossRef

65.

M.N. Rao et al., Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J. Clin. Endocrinol. Metab. 95, 4361–4366 (2010)PubMedCrossRef

66.

K.A. Lichtenstein et al., Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389–1398 (2001)PubMedCrossRef

67.

N. Gianotti et al., Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med. 12, 109–117 (2011)PubMedCrossRef

68.

A. Balasubramanyam, R.V. Sekhar, F. Jahoor, P.H. Jones, H.J. Pownall, Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’. Curr. Opin. Lipidol. 15, 59–67 (2004)PubMedCrossRef

69.

J.M. Lenhard et al., HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antivir. Res. 47, 121–129 (2000)PubMedCrossRef

70.

A.R. Miserez, P.Y. Muller, V. Spaniol, Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 16, 1587–1594 (2002)PubMedCrossRef

71.

D. Nolan, M. John, S. Mallal, Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir. Ther. 6, 145–160 (2001)PubMed

72.

S. Tsiodras, A. Perelas, C. Wanke, C.S. Mantzoros, The HIV-1/HAART associated metabolic syndrome—novel adipokines, molecular associations and therapeutic implications. J. Infect. 61, 101–113 (2010)PubMedCrossRef

73.

G.S. Nagy et al., Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin. Infect. Dis. 36, 795–802 (2003)PubMedCrossRef

74.

J.L. Chan, K. Heist, A.M. DePaoli, J.D. Veldhuis, C.S. Mantzoros, The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 111, 1409–1421 (2003)PubMed

75.

J.H. Lee, J.L. Chan, E. Sourlas, V. Raptopoulos, C.S. Mantzoros, Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91, 2605–2611 (2006)PubMedCrossRef

76.

K. Mulligan et al., The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J. Clin. Endocrinol. Metab. 94, 1137–1144 (2009)PubMedCrossRef

77.

T. Yamauchi et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288–1295 (2002)PubMedCrossRef

78.

T. Yamauchi et al., Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762–769 (2003)PubMedCrossRef

79.

M. Iwaki et al., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52, 1655–1663 (2003)PubMedCrossRef

80.

L. Kosmiski, D. Kuritzkes, K. Lichtenstein, R. Eckel, Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir. Ther. 8, 9–15 (2003)PubMed

81.

K. Falasca et al., Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann. Clin. Lab. Sci. 36, 59–66 (2006)PubMed

82.

C. Vernochet et al., Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem. 280, 2238–2243 (2005)PubMedCrossRef

83.

C.L. Addy et al., Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 88, 627–636 (2003)PubMedCrossRef

84.

R. Verkauskiene et al., Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr. Res. 60, 225–230 (2006)PubMedCrossRef

85.

P.W. Hruz, Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract. Res. Clin. Endocrinol. Metab. 25, 459–468 (2011)PubMedCrossRef

86.

W. Lewis, B.J. Day, W.C. Copeland, Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2, 812–822 (2003)PubMedCrossRef

87.

C.M. Shikuma, L.J. Day, M. Gerschenson, Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr. Drug Targets Infect. Disord. 5, 255–262 (2005)PubMedCrossRef

88.

M. Gerschenson, K. Brinkman, Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 4, 763–777 (2004)PubMedCrossRef

89.

H. Murata, P.W. Hruz, M. Mueckler, The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275, 20251–20254 (2000)PubMedCrossRef

90.

H. Murata, P.W. Hruz, M. Mueckler, Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16, 859–863 (2002)PubMedCrossRef

91.

M.A. Noor et al., Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15, F11–F18 (2001)PubMedCrossRef

92.

M.A. Noor et al., Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16, F1–F8 (2002)PubMedCrossRef

93.

A. Carr, K. Samaras, D.J. Chisholm, D.A. Cooper, Abnormal fat distribution and use of protease inhibitors. Lancet 351, 1736 (1998)PubMedCrossRef

94.

A.K. Vyas, J.C. Koster, A. Tzekov, P.W. Hruz, Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J. Biol. Chem. 285, 36395–36400 (2010)PubMedCrossRef

95.

J.C. Koster, M.S. Remedi, H. Qiu, C.G. Nichols, P.W. Hruz, HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52, 1695–1700 (2003)PubMedCrossRef

96.

M.A. Noor, O.P. Flint, J.F. Maa, R.A. Parker, Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20, 1813–1821 (2006)PubMedCrossRef

97.

P.W. Hruz, Q. Yan, Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model. J. Acquir. Immune Defic. Syndr. 43, 624–625 (2006)PubMedCrossRef

98.

J.A. Aberg et al., Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49, 651–681 (2009)PubMedCrossRef

99.

M. Schambelan et al., Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31, 257–275 (2002)PubMedCrossRef

100.

D.M. Nathan et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009)PubMedCrossRef

101.

International Expert Committee, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327–1334 (2009)CrossRef

102.

P.S. Kim et al., A1C underestimates glycemia in HIV infection. Diabetes Care 32, 1591–1593 (2009)PubMedCrossRef

103.

S.W. Worm et al., Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 119, 805–811 (2009)PubMedCrossRef

104.

A. Carr et al., Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288, 207–215 (2002)PubMedCrossRef

105.

A. Martin et al., Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18, 1029–1036 (2004)PubMedCrossRef

106.

G.A. McComsey et al., Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 38, 263–270 (2004)PubMedCrossRef

107.

A. Gavrila et al., Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin. Infect. Dis. 36, 1593–1601 (2003)PubMedCrossRef

108.

K.E. Yarasheski et al., Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90, 133–138 (2001)PubMed

109.

K.V. Fitch et al., Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20, 1843–1850 (2006)PubMedCrossRef

110.

E.S. Engelson et al., Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism 55, 1327–1336 (2006)PubMedCrossRef

111.

J.B. Albu, C.M. Kim, E.S. Engelson et al., Effects of diet and exercise and/or rosiglitazone on body composition and glucose metabolism in HIV+ and HIV− subjects. Antivir. Ther. 13(Suppl. 4), A31 (2008)

112.

T. Saint-Marc, J.L. Touraine, Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13, 1000–1002 (1999)PubMedCrossRef

113.

C. Hadigan et al., Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 86, 939–943 (2001)PubMedCrossRef

114.

Lactic Acidosis International Study Group, Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 21, 2455–2464 (2007)CrossRef

115.

L.T. Matthews et al., A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. PLoS One 6, e18736 (2011)PubMedCrossRef

116.

C. Hadigan et al., Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 140, 786–794 (2004)PubMed

117.

J. Sutinen et al., Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. Antivir. Ther. 8, 199–207 (2003)PubMed

118.

A. Carr et al., No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363, 429–438 (2004)PubMedCrossRef

119.

J. Sutinen, The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res. 2009, 373524 (2009)PubMedCrossRef

120.

S.E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457–2471 (2007)PubMedCrossRef

121.

FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm (2011). Accessed 4 November 2011

122.

A.M. Lincoff, K. Wolski, S.J. Nicholls, S.E. Nissen, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180–1188 (2007)PubMedCrossRef

123.

S.H. Sheth, R.J. Larson, The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect. Dis. 10, 183 (2010)PubMedCrossRef

124.

L. Slama et al., Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir. Ther. 13, 67–76 (2008)PubMed

125.

A. Gavrila et al., Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin. Infect. Dis. 40, 745–749 (2005)PubMedCrossRef

126.

R.W. Nesto et al., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108, 2941–2948 (2003)PubMedCrossRef

127.

P. Oriot, M.P. Hermans, P. Selvais, M. Buysschaert, X. de la Tribonniere, Exenatide improves weight loss insulin sensitivity and beta-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann. Endocrinol. (Paris) 72, 244–246 (2011)

128.

M. Briones, M. Bajaj, Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin. Pharmacother. 7, 1055–1064 (2006)PubMedCrossRef

129.

J.D. Lundgren et al., European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9, 72–81 (2008)PubMedCrossRef

Titel: Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management
verfasst von: Absalon D. Gutierrez
Ashok Balasubramanyam
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-011-9565-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Gitelman's syndrome: a pathophysiological and clinical update

A rare S33C mutation of CTNNB1 encoding β-catenin in a parathyroid adenoma found in an Italian primary hyperparathyroid cohort

Investigation of thyroid function and blood pressure in school-aged subjects without overt thyroid disease

Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study

Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed